Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Accumulated Expenses (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Accumulated Expenses for 13 consecutive years, with $9.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 69.21% to $9.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Dec 2025, up 69.21% year-over-year, with the annual reading at $8.8 million for FY2025, 294.18% up from the prior year.
  • Accumulated Expenses hit $9.3 million in Q4 2025 for Vistagen Therapeutics, up from $8.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9.3 million in Q4 2025 to a low of $35000.0 in Q2 2023.
  • Historically, Accumulated Expenses has averaged $3.0 million across 5 years, with a median of $2.2 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: crashed 88.8% in 2022 and later skyrocketed 6082.86% in 2024.
  • Year by year, Accumulated Expenses stood at $2.6 million in 2021, then crashed by 88.25% to $308800.0 in 2022, then plummeted by 58.13% to $129300.0 in 2023, then soared by 4129.7% to $5.5 million in 2024, then skyrocketed by 69.21% to $9.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for VTGN at $9.3 million in Q4 2025, $8.4 million in Q3 2025, and $6.6 million in Q2 2025.